PROF
Profound Medical Corp. NASDAQ Listed Oct 29, 2019$6.82
+3.81%
vs $6.57
Mkt Cap $206.2M
52w Low $3.87
61.7% of range
52w High $8.65
50d MA $6.73
200d MA $6.39
P/E (TTM)
4.8x
EV/EBITDA
—
P/B
2.3x
Debt/Equity
0.1x
ROE
-64.1%
P/FCF
-3.8x
RSI (14)
52.50
ATR (14)
$0.28
Beta
0.47
50d MA
$6.73
200d MA
$6.39
Avg Volume
69.2K
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
2400 Skymark Avenue · Mississauga, ON L4W 5K5 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.24 | -0.19 | +20.8% | 7.16 | +1.8% | -4.3% | +5.8% | -1.5% | -0.6% | +1.4% | — |
| Mar 5, 2026 | AMC | -0.27 | -0.27 | +0.0% | 7.49 | -13.1% | -29.1% | -1.5% | +3.4% | +3.7% | -1.1% | — |
| Nov 13, 2025 | AMC | -0.38 | -0.26 | +31.6% | 6.35 | -5.7% | +7.9% | -5.7% | -3.6% | -2.6% | -3.1% | — |
| Aug 14, 2025 | AMC | -0.43 | -0.52 | -20.9% | 5.54 | -7.4% | -23.3% | +11.8% | -3.6% | +1.3% | -0.9% | — |
| May 8, 2025 | AMC | -0.29 | -0.36 | -24.1% | 4.98 | -3.6% | -7.0% | -7.6% | -0.2% | -5.4% | +12.1% | — |
| Mar 6, 2025 | AMC | -0.31 | -0.20 | +35.5% | 7.29 | +1.6% | -5.9% | -1.7% | +1.2% | +4.4% | -1.7% | — |
| Nov 7, 2024 | AMC | -0.30 | -0.38 | -26.7% | 8.96 | +0.4% | -2.3% | -6.7% | -2.5% | +2.6% | -2.0% | — |
| Aug 8, 2024 | AMC | -0.29 | -0.28 | +3.4% | 9.62 | -1.4% | -2.8% | -7.2% | +8.1% | -0.7% | +1.7% | — |
| May 9, 2024 | AMC | -0.30 | -0.26 | +13.3% | 8.52 | +3.3% | -9.3% | -1.0% | +7.3% | +4.0% | -0.6% | — |
| Mar 7, 2024 | AMC | -0.32 | -0.42 | -31.2% | 9.02 | -6.9% | -10.9% | -0.4% | +2.4% | +1.8% | +2.2% | — |
| Nov 2, 2023 | AMC | -0.33 | -0.26 | +21.2% | 9.16 | +3.7% | +4.8% | -1.7% | -2.6% | +2.3% | +5.0% | — |
| Aug 9, 2023 | AMC | -0.34 | -0.35 | -2.9% | 10.43 | -0.5% | -3.0% | -3.9% | -0.9% | +0.3% | -8.6% | — |
| May 10, 2023 | AMC | -0.34 | -0.32 | +5.9% | 13.26 | +4.4% | +3.4% | +0.9% | -8.4% | +2.0% | +5.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 7 | Lake Street | Maintains | Buy → Buy | — | $7.73 | $7.78 | +0.6% | +6.2% | +3.3% | -0.5% | +2.5% | -3.1% |
| Apr 23 | Lake Street | Maintains | Buy → Buy | — | $4.67 | $4.90 | +4.9% | +0.4% | +0.6% | +0.8% | -0.4% | +3.2% |
| Jul 16 | Stifel | Upgrade | Hold → Buy | — | $9.15 | $9.99 | +9.2% | +6.0% | +0.4% | +2.6% | +2.3% | -0.2% |
| Mar 11 | Alliance Global Partners | Maintains | Buy → Buy | — | $8.04 | $8.00 | -0.5% | -0.4% | +2.4% | +1.8% | +2.2% | -0.1% |
| Mar 8 | Stifel | Maintains | Hold → Hold | — | $9.02 | $8.40 | -6.9% | -10.9% | -0.4% | +2.4% | +1.8% | +2.2% |
| Jan 4 | Alliance Global Partners | Maintains | Buy → Buy | — | $7.68 | $7.92 | +3.1% | -4.9% | +2.5% | +1.2% | -2.6% | +3.0% |
| Aug 4 | Raymond James | Downgrade | Strong Buy → Outperform | — | $10.12 | $10.09 | -0.3% | -3.7% | +3.3% | +6.0% | -2.2% | -3.0% |
| May 11 | Alliance Global Partners | Maintains | Buy → Buy | — | $13.26 | $13.84 | +4.4% | +3.4% | +0.9% | -8.4% | +2.0% | +5.0% |
| May 11 | TD Cowen | Maintains | Outperform → Outperform | — | $13.26 | $13.84 | +4.4% | +3.4% | +0.9% | -8.4% | +2.0% | +5.0% |
| Mar 21 | Jefferies | Downgrade | Buy → Equal Weight | — | $10.16 | $9.90 | -2.6% | -0.9% | -12.1% | +0.6% | +3.0% | -0.3% |
| Nov 4 | Raymond James | Upgrade | Outperform → Strong Buy | — | $3.92 | $4.06 | +3.6% | +18.6% | +8.0% | -3.4% | +1.0% | -3.7% |
| Mar 7 | TD Cowen | Maintains | Outperform → Outperform | — | $9.35 | $9.33 | -0.2% | -12.3% | +1.1% | -0.2% | +1.9% | -1.4% |
| Feb 22 | Raymond James | Downgrade | Strong Buy → Outperform | — | $9.51 | $8.95 | -5.9% | +6.2% | +0.4% | -1.4% | +6.8% | +0.1% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Profound Medical scheduled its Q1 2026 earnings release for May 7, 2026, signaling continued operational transparency and giving investors a specific date to anticipate financial performance and management guidance.
Apr 16
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Profound Medical (PROF) is presenting at a major healthcare investor conference, signaling management confidence in the company's story and providing potential catalysts for stock movement through investor exposure and analyst coverage.
Apr 14
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Profound's prominence at a major interventional radiology conference validates its TULSA-PRO technology and could drive clinical adoption and investor confidence in its commercial-stage MRI-guided ablation platform.
Apr 1
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Profound Medical's TULSA procedure milestone demonstrates growing clinical adoption and provider confidence, validating market demand for its MRI-guided prostate ablation technology and supporting revenue growth potential.
Mar 27
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
PROF's CAPTAIN trial exceeded enrollment targets (211 vs. 201 patients), suggesting strong clinical demand and potentially de-risking the TULSA procedure's regulatory pathway toward faster approval.
Mar 13
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Baylis's executive appointment with standard equity compensation and indemnification suggests stable leadership continuity, but investors should monitor whether this role fills a critical gap or represents routine management changes affecting PROF's strategic direction.
Mar 10
8-K · 7.01
! Medium
Profound Medical Corp. -- 8-K 7.01: Regulation FD Disclosure
Profound Medical will present clinical outcomes from its CAPTAIN trial on March 9, 2026, providing investors with key efficacy and safety data for its therapeutic program.
Mar 9
8-K
Profound Medical Corp. -- 8-K Filing
Profound Medical reported Q4 and full-year 2025 financial results, providing investors with performance metrics for the interventional MRI medical device company's commercial operations.
Mar 5
8-K · 7.01
! Medium
Profound Medical Corp. -- 8-K 7.01: Regulation FD Disclosure
Profound Medical scheduled a conference call and webcast for February 12, 2026, to discuss company updates with investors and analysts.
Feb 12
8-K · 7.01
! Medium
Profound Medical Corp. -- 8-K 7.01: Regulation FD Disclosure
Profound Medical Corp. disclosed material information via press release on February 12, 2026, requiring investor review of the furnished exhibit for complete details on the announcement.
Feb 12
8-K · 7.01
! Medium
Profound Medical Corp. -- 8-K 7.01: Regulation FD Disclosure
Profound Medical Corp. disclosed material information via press release on February 5, 2026, which investors should review as an official company communication.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Timelo Investment Management Inc. | 1,114,967 | $7M | Added | Mar 2026 |
| 2 | Letko, Brosseau & Associates Inc | 953,175 | $6M | Reduced | Mar 2026 |
| 3 | Rosalind Advisors, Inc. | 828,118 | $5M | Reduced | Mar 2026 |
| 4 | First Eagle Investment Management, Llc | 645,414 | $4M | Added | Mar 2026 |
| 5 | Ardsley Advisory Partners Lp | 575,000 | $4M | Added | Mar 2026 |
| 6 | Royal Bank Of Canada | 493,060 | $3M | Added | Mar 2026 |
| 7 | Velan Capital Investment Management Lp | 285,710 | $2M | — | Mar 2026 |
| 8 | Formula Growth Ltd | 241,138 | $2M | Added | Mar 2026 |
| 9 | Dauntless Investment Group, Llc | 240,739 | $2M | Added | Mar 2026 |
| 10 | Thompson Davis & Co., Inc. | 215,785 | $1M | — | Mar 2026 |
| 11 | Raymond James Financial Inc | 150,157 | $973K | Added | Mar 2026 |
| 12 | Td Waterhouse Canada Inc. | 143,041 | $902K | Added | Mar 2026 |
| 13 | Cm Management, Llc | 80,000 | $630K | New | Dec 2025 |
| 14 | Ubs Group Ag | 81,108 | $526K | Added | Mar 2026 |
| 15 | Truist Financial Corp | 50,000 | $394K | — | Dec 2025 |
| 16 | Northwest & Ethical Investments L.p. | 38,200 | $244K | — | Mar 2026 |
| 17 | Simplex Trading, Llc | 36,718 | $238K | Added | Mar 2026 |
| 18 | Centiva Capital, Lp | 29,280 | $190K | New | Mar 2026 |
| 19 | Focus Partners Wealth | 16,722 | $108K | — | Mar 2026 |
| 20 | Bank Of Montreal /can/ | 11,742 | $75K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 7
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | ROYCE MICRO-CAP TRUST, INC. | 691,021 | $4M | Mar 2026 |
| 2 | Royce Micro-Cap Fund | 322,570 | $2M | Mar 2026 |
| 3 | First Eagle Small Cap Opportunity Fund | 270,997 | $2M | Jan 2026 |
| 4 | Royce Capital Fund - Micro-Cap Portfolio | 102,757 | $657K | Mar 2026 |
| 5 | 1290 Essex Small Cap Growth Fund | 70,618 | $530K | Jan 2026 |
| 6 | Fidelity Nasdaq Composite Index Fund | 21,346 | $162K | Feb 2026 |
| 7 | Dimensional International Small Cap ETF | 908 | $7K | Jan 2026 |
Data updated apr 26, 2026 8:46pm
· Source: financialmodelingprep.com